At AseBio we would like to highlight the importance of biotechnology & life sciences in the recovery strategy for Spain and Europe as a whole, so we can be ready for future sanitary emergencies, achieve a healthier society and to foster a new cycle of green & sustainable economic growth.
The AseBio Health Innovation Forum is an event whose objective is to place biotechnology and life sciences at the heart of the recovery strategy and to create new collaboration and commercial opportunities through the partnering system.
All registered participants at the AseBio Health Innovation Forum will be able to organize a 1:1 meeting agenda thanks to our partnering system. Do not miss this opportunity if you are interested to explore new collaboration and business opportunities with the Spanish biotech & health ecosystem!
The mission letter to the recently appointed Health and Food Safety Commissioner Stella Kyriakides included the Europe’s Beating Cancer Plan as one of her missions. In this regard, the Plan should provide support to Member States to improve cancer prevention and care and propose actions to strengthen Europe’s approach at every key stage of the disease: prevention, diagnosis, treatment, life as a cancer survivor and palliative care. The need to strengthen links with the research mission on cancer in the future Horizon Europe programme is also highlighted.
In this regard, the Plan aims to support effective, accessible and resilient health systems across the different member states and in particular, to support Member States who are most in need of evidence-based policy making, to ensure that all EU citizens have access to effective cancer prevention and care.
The main objectives of the plan will be highlighted in this sessions, as well as its potential impact on the research, development and innovation ecosystems in Europe and specially, in Spain, where a national plan is expected to implement this new cancer strategy.
New breakthroughs in the field of biotechnology research obtained in recent years have allowed the development of innovative and revolutionary scientific strategies based on gene therapy, somatic cell therapy and tissue engineering, giving rise to a new category of drugs known as advanced therapies.
Since 2001, regulation at the European and national level has been shaping the framework for companies and the public sector in the production and use of advanced therapy drugs.
Spain has positioned itself as a benchmark country in advanced therapies both in research and in government initiatives with an Approach Plan at the state level.
Now is the time to highlight this area and the collaborative work that is being carried out, since it is expected that in the near future this group of drugs will be positioned as a cornerstone of the treatment of numerous key diseases with important medical needs still to be covered. At the moment, that there are currently about 960 advanced therapies in the R&D phase, around the world for the treatment of a hundred pathologies, of which 53% are focused on treating different types of cancer.
The development of genomics and proteomics, and the knowledge of the molecular bases associated with diseases, has allowed the arrival of a new era thanks to precision medicine. With the development of biomedical research, we increasingly have greater knowledge of the alterations in the genome responsible for diseases such as cancer, as well as those markers associated with the metabolism of certain drugs and therefore, their tolerability and toxicity.
There is no doubt that the development and adoption of precision medicine poses great challenges for healthcare systems and challenges the classic models of development and access to innovation. At the same time, it represents a great opportunity to be more efficient in the provision of health care, improve treatment expectations and the quality of life of patients, and generate opportunities for economic development.
How can we prepare for this new era and make the most of its opportunities?
This session will revolve around three thematic blocks:
- Comprehensive Strategy for Precision Medicine Navarre.
- Clinical development in precision medicine.
- Impact of precision medicine on the National Health System, opportunities and challenges.
The European Union Recovery Plan will mobilize resources to address the risks Europe faces, to build a more resilient European Union. The new pharmaceutical strategy will address the risks that have been exposed during the recent health crisis, such as drug production capacity, which may jeopardize Europe’s strategic autonomy.
To face these challenges, a regulatory and support framework for the industry and the R&D system will be created so that treatments reach patients even in times of instability such as the current one.
In this session we will be able to learn:
- The new European strategy for the biotechnological ecosystem (public and private) in Spain.
- How the companies and entities associated with AseBio can contribute to implement this plan in Spain.